MODEL SPOTLIGHT | LL/2 – An Immunosuppressive Murine Tumor Model
The advent of immunotherapy has necessitated syngeneic mouse tumor models to further advance the development of immuno-oncology treatments. One of these models is the LL/2 (Lewis Lung) lung carcinoma model that has been characterized to support development of novel agents and approaches to the treatment of “cold,” non-immunogenic tumors.
In this model spotlight our share LL/2 data regarding:
- Tumor Immune Profile
- Growth and Response to Doxorubicin and Paclitaxel Therapy
- Response to Checkpoint Inhibitors anti-mPD-1 and anti-mPD-L1
- Combination Treatment with Checkpoint Inhibitors and Paclitaxel
- Combination Treatment with Localized Radiation and anti-mPD-1
Discover the specifics around our LL/2 data and what this tumor model can support when conducting a preclinical immuno-oncology lung carcinoma study.